INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021

Rhea-AI Summary

INOVIO (NASDAQ: INO) will release its first quarter 2021 financial results on May 10, 2021, after market close. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss these results and provide an update on its DNA Medicines Platform, including ongoing COVID-19 vaccine developments. INOVIO's VGX-3100 has achieved efficacy endpoints in a Phase 3 trial for treating precancerous cervical dysplasia, marking a significant achievement in DNA medicine.

Positive

• VGX-3100 reached efficacy endpoints in Phase 3 trial for HPV-related conditions.
• Ongoing development for various infectious diseases and cancers demonstrates diversified pipeline.

Negative

• None.

PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company's ongoing vaccine developments for COVID-19.

A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts.

About INOVIO

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial, REVEAL 1, for the treatment of precancerous cervical dysplasia caused by HPV-16 and/or HPV-18. VGX-3100 also demonstrated positive Phase 2 efficacy results in separate trials evaluating the treatment of precancerous vulvar dysplasia and anal dysplasia. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and COVID-19 diseases. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. For more information, visit www.inovio.com.

CONTACTS:              
Investors:          Ben Matone, 484-362-0076, ben.matone@inovio.com
Media:              Jeff Richardson, 267-440-4211, jrichardson@inovio.com

View original content:http://www.prnewswire.com/news-releases/inovio-to-report-first-quarter-2021-financial-results-on-may-10-2021-301277656.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When will INOVIO report its financial results for the first quarter of 2021?

INOVIO will report its financial results after market close on May 10, 2021.

What time is INOVIO's conference call scheduled for following the Q1 2021 results?

The conference call is scheduled for 4:30 p.m. ET on May 10, 2021.

What is VGX-3100 and what recent achievement did it accomplish?

VGX-3100 is INOVIO's lead DNA medicine that has achieved efficacy endpoints in a Phase 3 clinical trial for treating precancerous cervical dysplasia.

What topics will be covered in INOVIO's conference call on May 10, 2021?

The conference call will cover Q1 financial results and updates on INOVIO's DNA Medicines Platform and COVID-19 vaccine developments.